FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Country

Certificates

FDA
Registration Date 16 Nov 2016
Share

Macugen

Medicine Pharmaceuticals Product Number : 68782-001-02

Ophthalmologic Agent

Drug Information

Generic
Pegaptanib
NDC Code
68782-001-02
Drug Class
Anti-angiogenic ophthalmic agents
Therapeutic Class
Ophthalmologic Agent
Dosage form
Solution
Route of Administration
INTRAVITREAL
Therapeutic Area
1.Age-related macular degeneration

Indication

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration.

Benefit

After one year of treatment, about 70% of the patients treated with Macugen 0.3 and 1 mg lost less than 15 letters in the eye test compared with about 55% of those who received the sham injection. The 3-mg dose did not bring any additional benefit. This improvement lasted for two years in patients who were given Macugen.